STOCK TITAN

ABVC BioPharma, Inc. - ABVC STOCK NEWS

Welcome to our dedicated page for ABVC BioPharma news (Ticker: ABVC), a resource for investors and traders seeking the latest updates and insights on ABVC BioPharma stock.

ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions in the fields of oncology/hematology, central nervous systems (CNS), and ophthalmology. Founded in 2015 and headquartered in Fremont, California, the company is focused on addressing unmet medical needs through its pipeline of innovative drugs and medical devices.

ABVC BioPharma, along with its subsidiaries like BioLite, Inc. and BioFirst Corporation, has an active pipeline comprising six drugs and one medical device (ABV-1701/Vitargus®) under development. ABVC harnesses licensed technology from renowned research institutions such as Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center to conduct proof-of-concept trials up to Phase II of clinical development. The company’s flagship product, Vitargus®, is a groundbreaking vitreous substitute for retinal detachment surgery and is currently undergoing global clinical trials.

The company’s drug candidates include:

  • ABV-1501 – A combination therapy for triple-negative breast cancer.
  • ABV-1504 – Designed for treating major depressive disorder (MDD).
  • ABV-1505 – Targets attention deficit hyperactivity disorder (ADHD).
  • ABV-1702 – For the treatment of myelodysplastic syndromes (MDS).
  • ABV-1703 – Focused on the treatment of pancreatic cancer.
  • ABV-1601 – Aimed at treating depression in cancer patients.

ABVC has entered several strategic partnerships and licensing agreements to advance its pipeline. These include co-development agreements with Rgene Corporation and BiohopeKing Corporation for ABV-1501, and collaborative efforts with BioFirst Corporation for the co-development of BFC-1401 vitreous substitute for vitrectomy and ABV-1701 Vitargus for retinal detachment or vitreous hemorrhage.

Recent achievements include a global licensing agreement with AiBtl BioPharma Inc. for CNS drugs targeting MDD and ADHD, valued at $667 million, and the acquisition of a U.S. patent for the use of PDC-1421 (Polygala extract) in treating ADHD. ABVC is also involved in strategic investments such as the acquisition of real estate in Taoyuan City, Taiwan, to develop plant factories for its botanical drug pipeline.

ABVC BioPharma is committed to bringing high-efficacy, low-toxicity botanically based solutions to the market, improving health outcomes for patients worldwide. The company’s focus on strategic partnerships, innovative research, and global clinical trials positions it as a significant player in the biopharmaceutical industry.

Rhea-AI Summary

ABVC BioPharma announces its ABV-1504 drug as a potential safer alternative to Prozac, which faces discontinuation due to side effects concerns. The drug's active ingredient, PDC-1421 (derived from Radix Polygala), has shown promising results in treating Major Depressive Disorder (MDD) and ADHD, achieving a MADRS score reduction of -13.21 from baseline over 6 weeks.

The company has completed Phase II clinical trials and is moving towards Phase III trials globally, with patents valid until 2041. The treatment demonstrates fewer adverse effects compared to traditional antidepressants, positioning it strategically in growing markets. The global MDD market is expected to reach $14.96 billion by 2032, while the ADHD treatment market shows a 7.3% CAGR through 2032.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.74%
Tags
none
-
Rhea-AI Summary

ABVC BioPharma (NASDAQ: ABVC) has received a $200,000 initial cash payment from OncoX BioPharma as part of a strategic licensing agreement for oncology-related products. This payment represents the first installment of a potential $5 million in licensing fees from OncoX. The company has now accumulated $546,000 in total cash payments from three strategic partners.

Under the agreement, ABVC and its subsidiaries BioLite Inc. and Rgene can each receive up to 10M OncoX shares, $5M in cash payments, and royalties up to $50M post-product launch. The partnership aims to advance breakthrough therapies in oncology, targeting a market projected to reach $393.61 billion by 2032 with a 9.20% CAGR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.5%
Tags
none
-
Rhea-AI Summary

ABVC BioPharma reported significant Q3 2024 financial improvements, achieving its first operational profit. Revenue increased to $389,276 from $15,884 in Q3 2023. Net loss decreased to $134,272 from $3.37 million, with EPS improving to $(0.02) from $(0.82). The company secured multiple licensing agreements, including partnerships with ForSeeCon Eye for Vitargus®, potentially generating $187 million. Clinical developments include completed Phase II trials for ABV-1504 in Major Depressive Disorder and ongoing Phase IIb trials for ADHD. Cash position improved to $137,344, with shareholders' equity at $7.98 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
Rhea-AI Summary

ABVC BioPharma has received an additional $50,000 in licensing fees from AiBtl BioPharma Inc., bringing the total payments from strategic partners to $346,000. This payment is part of a broader agreement related to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD). The pipeline is valued at $667M by third-party evaluators.

ABVC has received 23M AiBtl shares as part of the first milestone and will obtain royalties up to $100M after product launch. The company is positioned in growing markets, with the global MDD market projected to reach $14.96 billion by 2032 and the global ADHD treatment market expected to grow at a CAGR of 7.3% through 2032. The global botanical drug market is forecasted to reach $3.2 billion by 2030 with a CAGR of 39%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
-
Rhea-AI Summary

ABVC BioPharma (NASDAQ: ABVC) reported strong Q2 2024 financial results and strategic achievements. Key highlights include:

1. Executed global licensing agreements potentially providing up to $292 million in income
2. Received $116,000 in cash milestone income
3. Improved EPS by 86.8% year-over-year to -$0.09
4. Increased revenue to $117,142, up from $6,109 in Q2 2023
5. Maintained $7.8 million in shareholders' equity
6. Obtained multiple patents and FDA approvals for treatments in major depressive disorder, ADHD, and ophthalmology
7. Completed Phase II trials for MDD and initiated Phase IIb trials for ADHD

ABVC is focusing on advancing its pipeline, expanding partnerships, and driving sustainable growth in oncology/hematology, CNS, and ophthalmology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the acquisition of TT Life Company by its subsidiary AiBtl BioPharma Inc. for $8.33M, with 1.66M AiBtl shares exchanged at $5 per share. The strategic move aims to expand AiBtl's portfolio in precision medicine, leveraging TT Life's manufacturing capabilities. This acquisition will enhance AiBtl's global presence and innovation in AI-integrated products for consumer wellness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) has signed a global licensing agreement with OncoX for the treatment of NSCLC, expecting an aggregate income of $13.75M and royalties of up to $12.50M. The agreement covers the license for the clinical trial, registration, manufacturing, supply, and distribution rights of ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom for NSCLC treatment. ABVC and its affiliate will receive a license fee of $12.5M in cash or shares, with additional milestone payments and royalties. The collaboration aims to accelerate the availability of the treatment worldwide, leveraging the strengths of both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.93%
Tags
none
-
Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) announced a potential licensing deal with OncoX BioPharma, Inc. for its Oncology/Hematology pipeline, involving $50M in licensing fees, milestone payments, and royalties. The company has FDA-approved INDs for various cancer treatments using innovative active ingredients. The partnership aims to revolutionize the sector and create significant value for stakeholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
none
-
Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) announced a global licensing agreement with ForSeeCon Eye for its Ophthalmology pipeline, including the medical device Vitargus® valued at $187M. The deal covers clinical trials, registration, manufacturing, supply, and distribution rights, with ABVC receiving $30M upfront and potential milestones. The partnership aims to enhance patient care and revenue generation, with ABVC continuing as R&D partner for new ophthalmic products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.9%
Tags
none
Rhea-AI Summary
ABVC BioPharma, Inc. announces an agreement for the exchange of real estate for AIBL stock, valued at $7.6 million. The deal involves 1,533,333 shares at $5 per share, benefiting ABVC and its subsidiary BioLite, Inc. The transaction is expected to bring significant value to the assets and reduce manufacturing costs for drug products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none

FAQ

What is the current stock price of ABVC BioPharma (ABVC)?

The current stock price of ABVC BioPharma (ABVC) is $0.53 as of December 23, 2024.

What is the market cap of ABVC BioPharma (ABVC)?

The market cap of ABVC BioPharma (ABVC) is approximately 6.4M.

What does ABVC BioPharma, Inc. specialize in?

ABVC BioPharma specializes in developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology.

Where is ABVC BioPharma, Inc. headquartered?

ABVC BioPharma is headquartered in Fremont, California.

What are the key products in ABVC BioPharma’s pipeline?

Key products include ABV-1501 for triple-negative breast cancer, ABV-1504 for major depressive disorder, ABV-1505 for ADHD, ABV-1702 for MDS, ABV-1703 for pancreatic cancer, and ABV-1601 for depression in cancer patients.

What recent partnerships has ABVC BioPharma formed?

Recent partnerships include a global licensing agreement with AiBtl BioPharma Inc. for CNS drugs targeting MDD and ADHD, and a co-development agreement with Rgene Corporation and BiohopeKing Corporation for ABV-1501.

What is ABVC BioPharma’s flagship product?

ABVC BioPharma’s flagship product is Vitargus®, a vitreous substitute for retinal detachment surgery.

What recent achievements has ABVC BioPharma made?

Recent achievements include acquiring a U.S. patent for PDC-1421 for ADHD treatment and the acquisition of real estate in Taiwan for developing plant factories.

What is the focus of ABVC BioPharma’s research?

ABVC BioPharma focuses on developing botanically based solutions with high efficacy and low toxicity to improve health outcomes.

Who are some of ABVC BioPharma’s research partners?

Research partners include Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.

How does ABVC BioPharma aim to improve patient outcomes?

ABVC BioPharma aims to improve patient outcomes through innovative, high-efficacy, low-toxicity botanically based solutions.

What can investors expect from ABVC BioPharma in the future?

Investors can expect continued innovation, strategic partnerships, and the global advancement of ABVC BioPharma’s therapeutic solutions.

ABVC BioPharma, Inc.

Nasdaq:ABVC

ABVC Rankings

ABVC Stock Data

6.38M
10.13M
22.93%
3.01%
1.5%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FREMONT